ArticleTranslational andrology and urology2026
Superior penile girth retention with stromal vascular fraction-enriched autologous fat grafting: a retrospective 1-year comparative study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fat resorption limits long-term outcomes of fat grafting for penile girth augmentation. Stromal vascular fraction (SVF)-enriched fat may improve graft survival by promoting angiogenesis, modulating inflammation, and via other paracrine effects. To our knowledge, no prior studies employed SVF for penile aesthetic procedures. In this retrospective non-randomized study, we aimed to assess the safety and clinical performance of SVF-enriched fat grafting versus Coleman fat. Methods: For the treatment group (n=50), protocol key steps included liposuction, non-enzymatic extraction of SVF via a novel device, fat enrichment, and graft injection, avoiding the corpora cavernosa. The Coleman fat group (n=38) received conventional grafting. Penile girth and length (flaccid and erect) and International Index of Erectile Function-5 scores were evaluated at baseline and at 1, 3, 6, and 12 months. Satisfaction was recorded at 12 months. Men with mild erectile dysfunction (n=10 and n=17 in the Coleman fat and treatment groups, respectively) also completed the full questionnaire about erection. The primary outcome was change in penile girth. Exploratory outcomes included change in penile length, erectile function, and patient-reported satisfaction with the procedure. Results: At 12 months, the treatment group showed significantly higher volume retention across all measurements (P<0.001), greater satisfaction (4.2/5 versus 3.7/5; P=0.01), and improvement of erection in mild erectile dysfunction cases (P=0.002). Changes were as follows (treatment versus Coleman fat, mean in centimeters): flaccid girth: +2.8 versus +1.6; erect girth: +1.9 versus +1.0; flaccid length: +1.0 versus +0.6; erect length: +0.8 versus +0.4. Two patients in each group had minor wound infections. Conclusions: SVF-enriched penile fat grafting improved volume retention with favourable functional outcomes in mild erectile dysfunction, supporting the feasibility of this approach in the penile setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.